# Contents

**Preface** xvii

**Editor's Note** xviii

**Dedication** xix

1. **Separations in Pharmaceutical Manufacturing** 1

   *Wayne P. Olson*

   Pure Drugs v. Crude Preparations: Conventional Pharmaceuticals v. Folk Medicine 1

   Developing a Drug (Apart from Regulatory Issues) 2

       Developing a Bioassay 2

       Developing a Chemical/Chromatographic/Biochemical Assay 2

       Purifying the Drug 3

       Scaleup of the Manufacturing Process 4

   **Sizing a Chromatographic System** 4

       Market Projections 4

       QC Costs and the Value of Product at Risk 5

       Dosage, Demand for Product, and QC Costs 5

       Column Life 5

       Purification Schemes 6

       Separations Based on Analytical Systems 6

   **Purification Methods** 8

       Particle Separations 8

       Molecular Separations and Conversions 13

   **Purification Steps and Yield** 28

   **Isolators** 28
Contents

Scaleup from a Published Bench Method 31

Automation 32

References 32

2. MEMBRANE PERVERAPORATION 39

Timothy de Villiers Naylor

Principles of Pervaporation 40

Factors Affecting Membrane Performance 42
  Feed Flow Rate 42
  Feed Temperature and Composition 43
  Downstream Pressure 44
  Membrane Type 45
  Module Design 46

Energy Requirements 48
  Pervaporation 48
  Distillation 49

Application Opportunities 50
  Feedstocks 50
  Case Studies 51

Conclusions 53

References 54

3. TANGENTIAL FLOW FILTRATION 57


The History of Tangential Flow Filtration 57

Principles and Theory 59
  Interplay of Hydrodynamics and Mass Transport in Tangential Flow Filtration 59
Polarization: Its Effects and Significance in Membrane Filtration 61

Physicochemical Factors Influencing Polarization 68

The Role of Membrane Surface Texture in Polarization 69

Membrane/Solute Interactions and Membrane Fouling 70

Product Recovery by Diafiltration: Effects of Polarization and Fouling 73

Polarization and Fouling in Perspective 74

Tangential Flow Filtration Equipment 75

Membrane Types and Materials 75

Device Types 77

Selection Criteria for Tangential Flow Devices 91

Components in Tangential Flow Filtration Systems 94

Application Classes in Pharmaceutical Separations 113

Clarification of Antibiotic Fermentation Broths 113

Clarification of and Cell Removal from Biological Cultures 120

Lysed Cell Separations: Clarification and Purification of Intracellular Proteins 126

Precolumn Clarification 132

Macromolecular Concentration and Diafiltration 133

Virus Concentration and Diafiltration 135

Macromolecular Separations (High-Resolution Tangential Flow Filtration) 140

Virus Removal from Biopharmaceuticals 149

Small Molecule Concentration and Desalting by Reverse Osmosis and Nanofiltration 155

Organic Solvent Removal and Exchange by Ultrafiltration or Reverse Osmosis 160

Endotoxin Removal by Ultrafiltration 164

Principles of Tangential Flow Filtration Maintenance 170

Flushing 171

Cleaning and Depyrogenation 173

Sanitization 176
5. **Preparative Separation of Enantiomers**  
*Charles M. Grill, John R. Kern, Scott R. Perrin*

**Practical Aspects**  
- Chiral Stationary Phases 236  
- Solvent Strength 238  
- Sample Mass 238

**Optimization Strategy**  
- Column Selection 239  
- Loading Capacity and Recovery 239  
- Isolation 240  
- Column Longevity 241  
- Scaleup 241

**Preparative Chromatographic Resolution of the α-Burke Olefin** 242

**Resolution of Racemates by Closed Loop Recycling Chromatography** 245

**Continuous Preparative Techniques for Resolving Racemic Mixtures** 252  
- Batch Chromatography 253  
- Liquid-Liquid Countercurrent Chromatography 258  
- Simulated Moving Bed Chromatography 261  
- Advantages of Simulated Moving Bed Chromatography Relative to Batch High Pressure Liquid Chromatography 264  
- Examples of the Use of Simulated Moving Bed Chromatography to Resolve Racemic Mixtures 265

**New Techniques** 267  
- Hollow-Fiber Membrane Reactors 267

**References** 267
6. **CHROMATOGRAPHIC PURIFICATION OF RECOMBINANT PROTEIN PRODUCTS**  
Eugene P. Kroeff

Purification Challenges  
System Selectivity  
Chromatographic Mode  
Product Form  
System Selectivity: Practical Considerations

Process Reproducibility  
Stationary Phase Integrity  
Mobile Phase

Process Scaleup Considerations  
Lab Scale Studies and Process Design  
Pilot Plant Studies  
Production Operations

Examples of Chromatographic Purification of rDNA Products  
Literature  
Production and Purification of Biosynthetic Human Insulin  
Preparation of Chimeric Human Proinsulin Reference Standard

Summary

References

7. **AFFINITY CHROMATOGRAPHY**  
Wayne P. Olson

Definitions  
Origins of Affinity Separations  
Affinity Pairs: Examples
Contents ix

Antigen-Antibody 307
Protein A/Protein G-Antibody 307
Lectin-Glycoproteins and Saccharides 308
Enzyme-Inhibitor 310
Cytokine-Receptor 311
Heparin Sulfate-Clotting Factors and HS-Antithrombin 311
Gelatin-Fibronectin 313
Chelated Metal-Protein 314
Dye-Protein with a Complementary Cleft 315
Polymyxin B-Endotoxin for Depyrogenation 316
Covalent Disulfide Chromatography with SH-Proteins 317
Thiophilic Adsorption of Immunoglobulins 317
Fusion Proteins with Metals, Glutathion, or Maltose 318
Other Affinity Pairs 319

Matrices of Choice 319
Agarose 319
Cellulose 320
Acrylamide and Related Materials 321
Microporous Glass 323
Cellulose-Based Nonwoven Filters 323
Cellulose-Based Membrane Filters 324
Noncellulosic Woven and Nonwoven Fibers 325
Novel Systems 325

Ligand Immobilization Chemistries 329
Epoxy (Oxirane) Activation 329
Succinic or Glutaric Anhydride 330
Sulfonyl Chlorides 330
Divinylsulfone 330
Carbodiimide 331
Chloroformates 331
Triazines, Including Dyes 331
Iminodiacetic Acid for Chelated Metals 332
8. MONOCLONAL ANTIBODIES

Gary Christiansen

Definitions

Historical Notes

The Production of Monoclonal Antibodies

The Fusion Process
In Vivo Production
In Vitro Production

Purification Objectives and Goals

Challenges
Regulatory Requirements
Validation Requirements for Purification
Virus Removal and Inactivation
DNA and Nucleic Acid Removal
Pyrogen Removal
Quality Control of the Monoclonal Antibody

Purification Methods

Miscellaneous Classical Methods
Chromatographic Methods
9. IMMUNOAFFINITY PURIFICATION OF PROTEINS FOR INJECTION, AND THE ISSUE OF ANIMAL VIRUSES 391
Wayne P. Olson

Immobilized Antigens and Antibodies—A Research Tool 391
Campbell et al. and Early Immunosorbent Work 391
Popularization of the Method 391
Evaluation of the Product 394

Immunosorbents for the Purification of Human Clotting Factor VIII for Injection 394
Economic Incentives for Dramatic Changes in Preparative Methods 394
Why Monoclonal Antibodies 395
The Scripps Clinic Approach 396
Hyland's Method M 398

The Issue of Virus Elimination and/or Destruction 401
Viruses in Human-Source F-VIII 401
Viruses and Other Materials in Recombinant Factor VIII 402
The New York Blood Center Method for Destruction of Enveloped Viruses 403
Elution of Viruses from Factor VIII Immunosorbent Columns 404
Dry Heating 405
Current Status of Human-Source and Recombinant F-VIII 405

Preferred Methods for Antibody Immobilization 405

The Matrix 405

The Cyanogen Bromide Method: Issues and Improvements 407

Periodate Oxidation of the Fc Saccharide 409

Sulphhydryl Coupling of Fab Fragments 409

The Nickel Affinity Approach 410

Other Methods 411

Scaling from the Limiting Step in Process 411

Charging and Eluting the Column 412

Avoiding Contamination of the Column 412

Charging and Rinsing Polyclonal and Monoclonal Columns 412

Elution Schemes for Polyclonal and Monoclonal Columns 413

Minimal Denaturation of Product and Antibodies 413

Issues with Immobilized Antibodies 414

Column Half-Life 414

Column Sanitization and Storage 414

Column Clogging and Repacking 414

Bleed of the Antibody into the Product 415

Potential Advantage of the Nickel Affinity Method 415

Phage Antibodies 415

Automation of the Cycle 416

Cell Purification with Immobilized Antibodies 417

Comparison of Immunosorbent with Other Methods 419

References 419
10. **Process Validation of Separation Systems** 427  
*Steven S. Kuwahara, Jane H. Chuan*

**Types of Validation** 427  
- Prospective Process Validation 428  
- Concurrent Process Validation 428  
- Retrospective Process Validation 428

**Why Validate?** 429  
- Practical Considerations 429  
- Process Control 429  
- Regulatory Requirements 429

**Who, What, and Where to Conduct Validations** 430  
- Where 430  
- Problems of Scale 430  
- Safety Issues 431  
- Employee Qualifications and Realistic Solutions 431  
- Selection of Models 431

**Extent of Validations** 432  
- Cost Considerations 432  
- Statistical Needs 433

**General Considerations** 434  
- Differences Between Synthetic Drugs and Secondary Metabolites Versus Biologics 434  
- What Needs to Be Validated 434

**Getting Started: What Needs to Be in Place Before Beginning Your Validation** 440  
- Validation Protocol 440

**Separation Systems** 441  
- Extractions and Partitions 441  
- Liquid-Solid Separations 442
Contents

Chromatography  443
Isoelectric Focusing, Chromatofocusing, Isotachophoresis, Electrophoresis  447
Filtration Processes  447

References  448

11. A SALUTE TO THE HUMAN PLASMA PROCESSING INDUSTRY AND ITS FOUNDERS, E. J. COHN ET AL.  453

Robert Tenold

Fractionation Automation  460

Centrifuges  460
The Sharples™ Centrifuge  460
Westphalia™ Centrifuges  462
Ultracentrifuges  462
Other Centrifugals  463

Filters and Process Filter Media  463
Plate and Frame Filter  464
Disposable Filter Cartridges  464
Filter and Basket Fuges  464
Funda Filters  465

Wiped or Thin Film Evaporation Systems  465
Rodney Hunt—Luwa Systems  465

Screen Systems  466
Sweco Shaker  466

Ultrafiltration/Diafiltration  467
Hollow-Fiber Media  467
Spiral and Thin Channel Media  468

Gel Chromatography  468
Exclusion and Gel Columns  468
Ion-Exchange Resins  469